EAM
PDSB icon

Eagle Asset Management’s PDS Biotechnology PDSB Stock Holding History

Eagle Asset Management’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-44,104
Closed -$8.27M – 641
2017
Q4 		$8.27M Buy
44,104
+1,805
+4% +$363K 0.05% 350
2017
Q3 		$9.19M Sell
42,299
-2,769
-6% -$573K 0.05% 338
2017
Q2 		$9.25M Buy
45,068
+70
+0.2% +$13.8K 0.06% 330
2017
Q1 		$8.2M Buy
44,998
+1,876
+4% +$372K 0.05% 348
2016
Q4 		$10.8M Buy
43,122
+1,146
+3% +$260K 0.07% 322
2016
Q3 		$8.74M Buy
41,976
+1,161
+3% +$230K 0.06% 339
2016
Q2 		$8.25M Sell
40,815
-2,730
-6% -$483K 0.06% 342
2016
Q1 		$7.97M Sell
43,545
-354
-0.8% -$63.3K 0.06% 346
2015
Q4 		$10.9M Buy
+43,899
New +$14.2M 0.07% 324

Other funds holding PDSB

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Eagle Asset Management's PDSB Position: Q1 2018 in Review

Eagle Asset Management sold out of PDS Biotechnology (PDSB) in Q1 2018, closing a stake of 44,104 shares — an estimated $8.27M sold.

Eagle Asset Management first reported a position in PDSB in Q4 2015 and held it in 9 quarters. The position peaked at $10.9M in Q4 2015. 60 funds tracked by Wall St. Rank hold PDSB as of Q1 2018.

  • Eagle Asset Management reported no remaining PDS Biotechnology position as of Q1 2018 after selling out during the quarter.
  • Eagle Asset Management sold 44,104 PDS Biotechnology shares in Q1 2018, an estimated $8.27M.
  • Eagle Asset Management first reported a position in PDS Biotechnology in Q4 2015 and held it in 9 quarters.
  • Eagle Asset Management's PDS Biotechnology position peaked at $10.9M in Q4 2015.
  • 60 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2018.

Based on Eagle Asset Management's 13F filing for Q1 2018, filed 9 May 2018.